🚀 It highlights the shift from transient transfection to stable production systems.
🔬 This new approach aims to enhance scalability, control, and product quality for ex vivo and in vivo therapies.
💡 Expert Brianna Jayanthi presents case studies that evaluate different LVV production methods, emphasizing their suitability for various applications.
📅 A Q&A session follows her presentation.
Introduction:
This article discusses advancements in lentiviral vector (LVV) manufacturing, focusing on the challenges associated with traditional transient transfection systems and the emerging stable production methods that promise to improve scalability, control, and quality in the production of LVVs for gene therapy applications.
- Growing interest in LVVs for in vivo therapies demands high-quality vectors that can be produced at scale.
- Traditional transient transfection systems face limitations in scalability and product quality.
- Stable LV production systems are being adopted to align LVV manufacturing with established practices for protein biologics.
- Brianna Jayanthi, PhD, showcases how Asimov’s LV Edge Producer and Packaging Systems enhance cell line quality and productivity.
- A case study contrasts transient, semi-stable, and stable LVV production systems, offering guidance for selecting suitable methods for different therapeutic applications.
Conclusion:
The article emphasizes that the transition to stable lentiviral vector production systems presents a significant improvement for clinical and commercial applications. This advance not only enhances the quality and productivity of LVVs but also addresses the pressing need for scalable manufacturing solutions in the evolving field of gene therapy.
